vs

Side-by-side financial comparison of Orchid Island Capital, Inc. (ORC) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $37.2M, roughly 1.0× Organogenesis Holdings Inc.). On growth, Orchid Island Capital, Inc. posted the faster year-over-year revenue change (372.6% vs -57.1%). Over the past eight quarters, Orchid Island Capital, Inc.'s revenue compounded faster (301.6% CAGR vs -46.5%).

Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ORC vs ORGO — Head-to-Head

Bigger by revenue
ORC
ORC
1.0× larger
ORC
$38.5M
$37.2M
ORGO
Growing faster (revenue YoY)
ORC
ORC
+429.6% gap
ORC
372.6%
-57.1%
ORGO
Faster 2-yr revenue CAGR
ORC
ORC
Annualised
ORC
301.6%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ORC
ORC
ORGO
ORGO
Revenue
$38.5M
$37.2M
Net Profit
$103.4M
Gross Margin
30.8%
Operating Margin
-185.1%
Net Margin
268.7%
Revenue YoY
372.6%
-57.1%
Net Profit YoY
1764.9%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ORC
ORC
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$38.5M
$225.6M
Q3 25
$26.9M
$150.9M
Q2 25
$23.2M
$101.0M
Q1 25
$19.7M
$86.7M
Q4 24
$126.7M
Q3 24
$340.0K
$115.2M
Q2 24
$-697.0K
$130.2M
Net Profit
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
$103.4M
$43.7M
Q3 25
$72.1M
$21.6M
Q2 25
$-33.6M
$-9.4M
Q1 25
$17.1M
$-18.8M
Q4 24
$7.7M
Q3 24
$17.3M
$12.3M
Q2 24
$-5.0M
$-17.0M
Gross Margin
ORC
ORC
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ORC
ORC
ORGO
ORGO
Q1 26
-185.1%
Q4 25
28.1%
Q3 25
13.7%
Q2 25
-12.5%
Q1 25
-30.9%
Q4 24
8.1%
Q3 24
5.4%
Q2 24
-10.7%
Net Margin
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
268.7%
19.4%
Q3 25
267.8%
14.3%
Q2 25
-145.0%
-9.3%
Q1 25
86.9%
-21.7%
Q4 24
6.1%
Q3 24
5094.1%
10.7%
Q2 24
714.3%
-13.1%
EPS (diluted)
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
$0.31
Q3 25
$0.11
Q2 25
$-0.10
Q1 25
$-0.17
Q4 24
$0.05
Q3 24
$0.09
Q2 24
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ORC
ORC
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$665.9M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.4B
Total Assets
$11.7B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ORC
ORC
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$665.9M
$93.7M
Q3 25
$583.9M
$63.7M
Q2 25
$440.8M
$73.1M
Q1 25
$396.4M
$110.0M
Q4 24
$135.6M
Q3 24
$322.1M
$94.3M
Q2 24
$241.0M
$89.9M
Total Debt
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
$1.4B
$300.1M
Q3 25
$1.1B
$255.1M
Q2 25
$912.0M
$233.2M
Q1 25
$855.9M
$242.9M
Q4 24
$262.9M
Q3 24
$656.0M
$278.5M
Q2 24
$555.9M
$263.5M
Total Assets
ORC
ORC
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$11.7B
$598.7M
Q3 25
$9.1B
$509.8M
Q2 25
$7.6B
$461.1M
Q1 25
$7.3B
$467.4M
Q4 24
$497.9M
Q3 24
$5.9B
$446.3M
Q2 24
$4.9B
$443.2M
Debt / Equity
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ORC
ORC
ORGO
ORGO
Operating Cash FlowLast quarter
$120.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.16×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
$120.4M
$39.4M
Q3 25
$28.0M
$3.1M
Q2 25
$18.4M
$-32.9M
Q1 25
$25.8M
$-19.9M
Q4 24
$10.9M
Q3 24
$-14.8M
$8.7M
Q2 24
$19.3M
$4.7M
Free Cash Flow
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
ORC
ORC
ORGO
ORGO
Q1 26
Q4 25
1.16×
0.90×
Q3 25
0.39×
0.14×
Q2 25
Q1 25
1.51×
Q4 24
1.43×
Q3 24
-0.86×
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons